The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales.This data release includes the care process and treatment target measurements for the full 2024-25 audit period (1 April 2024 – 31 March 2025); presented for England primary care, Wales primary care and specialist services (hospital-based care), each with its own separate data file.Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the April 2024 to March 2025 cut of this data being taken in May 2025. Data from Wales was received in July 2025.Please note that from 2024-25, the audit period changed from a 15-month period to a 12-month period. For example, the 2023-24 audit period covered January 2023 to March 2024 whereas for 2024-25 the audit period covered April 2024 to March 2025. This means that figures for 2024-25 onwards should not be compared with figures from earlier audit periods. The impact of this audit period change has been published (see related links).
Source link
Leave a Reply